Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AffaMed Approved to Begin China Phase III Trial of Candidate for Dry AMD

publication date: Sep 28, 2023

Shanghai AffaMed will begin China Phase III trials of Risuteganib (luminate®), its first-in-class injectable ophthalmic intravitreal candidate for intermediate dry age-related macular degeneration (Dry AMD). Luminate® is a first-in-class integrin regulator that regulates multiple pathways of oxidative stress response, including mitochondrial dysfunction, which contributes to intermediate Dry AMD. In 2021, AffaMed acquired greater China rights (including manufacturing) to the candidate from South Korea’s Hanmi Pharma in a $145 million agreement. AffaMed believes AM011 will be the first product in China to start Phase III development for Dry AMD. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital